Koneksa Strengthens Leadership Team with Appointment of Eric Luthi as Chief Business Officer

Koneksa, a leader in healthcare technology specializing in evidence-driven digital biomarkers, has appointed Eric Luthi as its new Chief Business Officer. With more than 25 years of experience in the life sciences sector, Mr. Luthi will oversee corporate and business development efforts in this newly established position.

Chris Benko, CEO and Co-Founder of Koneksa, said in a statement, “We’re thrilled to welcome Eric to lead our business development team. With his extensive industry expertise and proven success in driving growth and strategy, Eric will play a pivotalrole in advancing our strategic initiatives and forming essential partnerships with leading healthcare organizations. Hisleadership will be invaluable as we empower biopharma companies to utilize digital biomarkers to accelerate clinical trials and unlock critical data insights.”

Before joining Koneksa, Mr. Luthi was the Chief Commercial Officer at Evergreen Therapeutics, where he established the company's commercial function and spearheaded the launch strategy for its diagnostic radiopharmaceutical. Eric has a wealth of experience in commercial leadership, having worked with both large and small pharmaceutical companies across the US, Canada, and Switzerland. During his 20 years at Merck & Co., Inc., Eric played a pivotal role in aligning research and commercial strategies across various key therapeutic areas. 

Eric Luthi, Chief Business Officer, Koneksa, mentioned, “I’m honored to join Koneksa as we continue to advance the role of evidence-based digital biomarkers in clinical trials to accelerate decision making and improve patient outcomes. Our Commitment to leveraging advanced technology and real-time data streaming for data-driven insights is unparalleled. Our recent data syndication efforts encourage pre-competitive collaboration among companies to validate novel digital endpoints to provide baseline disease metrics in Parkinson’s disease. This approach not only benefits our partners but also supports improved patient outcomes. I’m excited to expand these partnerships and drive similar initiatives across additional therapeutic areas.”

He also led the commercial efforts for cardiovascular products in clinical development, working closely with R&D leadership. As the head of Digital and Commercial Operations at Merck's Canadian subsidiary, Eric focused on enhancing customer engagement and driving revenue growth by merging digital and traditional marketing strategies. He holds a Bachelor of Science in Biology and Psychology from Muhlenberg College.